Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Edgewise Therapeutics , Inc. (NASDAQ:EWTX), with a market capitalization of $2.67 billion, is a biopharmaceutical company focused on developing innovative therapies for severe, rare muscle disorders.

On Monday, Edgewise Therapeutics, Inc., (NASDAQ:EWTX) revealed topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy (BMD), is a genetic ...

Meanwhile, despite recent positive trial data, the analyst is not yet convinced of the prospects of sevasemten, an experimental therapy for a rare disorder called Becker muscular dystrophy.

Becker muscular dystrophy tends to appear later than the most common form of the disease, Duchenne MD (DMD). Symptoms may appear as late as age 25. Becker MD also progresses slower than DMD and is ...

Secondly, the goal is to develop this anti-myostatin drug to target other neuromuscular disorders like Duchenne Muscular Dystrophy [DMD], Becker Muscular Dystrophy [BMD], Amyotrophic Lateral ...

A cure is not possible with a very small version of the protein, Kelly explained, so the goal of current gene therapies is not to cure but to transform DMD into the less severe Becker muscular ...

Two of these patients were subsequently diagnosed with Becker muscular dystrophy and one child was diagnosed with mini-core myopathy. In the remaining seven patients the diagnosis was revised to ...